IQVIA Holdings Inc. (IQV)
| Market Cap | 31.19B +24.4% |
| Revenue (ttm) | 16.63B +7.3% |
| Net Income | 1.39B +3.8% |
| EPS | 8.07 +9.9% |
| Shares Out | 166.90M |
| PE Ratio | 23.15 |
| Forward PE | 14.22 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,676,397 |
| Open | 185.44 |
| Previous Close | 182.05 |
| Day's Range | 182.59 - 188.86 |
| 52-Week Range | 143.00 - 247.05 |
| Beta | 1.21 |
| Analysts | Strong Buy |
| Price Target | 227.10 (+21.52%) |
| Earnings Date | Jul 21, 2026 |
About IQV
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers ... [Read more]
Financial Performance
In 2025, IQVIA Holdings's revenue was $16.31 billion, an increase of 5.87% compared to the previous year's $15.41 billion. Earnings were $1.36 billion, a decrease of -0.95%.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for IQV stock is "Strong Buy." The 12-month stock price target is $227.1, which is an increase of 21.52% from the latest price.
News
IQVIA Announces Pricing of Senior Notes
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of €950,000,000 ...
IQVIA Holdings Transcript: Jefferies Global Healthcare Conference 2026
The conference highlighted strong Q1 performance, with both clinical and commercial segments exceeding expectations. AI is accelerating operational efficiency and revenue, while demand is rebounding across large pharma and EBP, supported by increased outsourcing and specialized engagement.
Iqvia price target lowered to $210 from $240 at HSBC
HSBC lowered the firm’s price target on Iqvia (IQV) to $210 from $240 and keeps a Buy rating on the shares. The firm says market expectations on life science tools…
IQVIA Announces Offering of Senior Notes
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise €950,000,000 throu...
IQVIA CEO to Speak at Jefferies Global Healthcare Conference
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
Iqvia, Kexing expand strategic collaboration
Iqvia (IQV) is advancing its strategic collaboration with Kexing Biopharm to support a global, multi-product biosimilar development and commercialization program. The collaboration is designed to supp...
IQVIA and Kexing Biopharm Expand Strategic Collaboration to Accelerate Global Biosimilar Development using AI-Enabled Capabilities
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healt...
IQVIA Holdings Transcript: Bank of America Global Healthcare Conference 2026
Q1 results exceeded expectations with strong growth in both commercial and RDS segments, supported by robust demand and AI-driven productivity. AI adoption is accelerating across top pharma clients, driving new offerings and operational efficiencies. Capital deployment favors buybacks, with ongoing M&A activity and increased investment in AI initiatives.
Iqvia approves $2B increase to share repurchase authorization
Iqvia (IQV) Holdings announced that its board authorized the repurchase of an additional $2B of Iqvia’s common stock under Iqvia’s existing equity repurchase program, bringing the total remaining auth...
IQVIA Board of Directors Approves $2 Billion Increase in Share Repurchase Authorization
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
Iqvia price target lowered to $225 from $240 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Iqvia (IQV) to $225 from $240 and keeps an Overweight rating on the shares.
IQVIA CFO to Speak at Bank of America Health Care Conference 2026
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
IQVIA Holdings Earnings Call Transcript: Q1 2026
Record Q1 revenue and EPS exceeded guidance, driven by strong organic growth in both Commercial and R&D Solutions, robust AI adoption, and a record backlog. Full-year guidance was reaffirmed and EPS outlook raised, with continued strong demand and constructive market conditions.
IQVIA Holdings Earnings release: Q1 2026
IQVIA Holdings released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
IQVIA Holdings Slides: Q1 2026
IQVIA Holdings has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
IQVIA Holdings Quarterly report: Q1 2026
IQVIA Holdings has published its Q1 2026 quarterly earnings report on May 5, 2026.
IQVIA Reports First-Quarter 2026 Results
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
IQVIA to Announce First-Quarter 2026 Results on May 5, 2026
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
Iqvia price target lowered to $185 from $225 at Evercore ISI
Evercore ISI analyst Elizabeth Anderson lowered the firm’s price target on Iqvia (IQV) to $185 from $225 and keeps an Outperform rating on the shares. The firm made several price…
IQVIA Unveils IQVIA.ai, a Unified Agentic AI Platform Powered by NVIDIA to Improve Efficiency and Decision Making Across Life Sciences
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, today announced...
IQVIA Holdings Transcript: Barclays 28th Annual Global Healthcare Conference
AI is driving revenue and margin growth, with over 150 agents deployed and plans for 500+ by 2027. Demand is strong, especially in biotech, which is expanding into clinical and commercial stages. Recent acquisitions enhance drug discovery capabilities, while productivity programs and automation support margin expansion.
IQVIA Holdings Transcript: Leerink Global Healthcare Conference 2026
AI is driving efficiency and new revenue streams, supported by proprietary data and advanced agent deployment. Market stability has returned post-COVID, with biotech and large pharma fueling growth. The Cedar Gate acquisition enhances US patient analytics and real-world evidence capabilities.
Iqvia upgraded to Buy from Hold at TD Cowen
TD Cowen upgraded Iqvia (IQV) to Buy from Hold with a price target of $213, up from $174. The firm does not see AI driving revenue headwinds for the company.
Iqvia price target raised to $213 from $174 at TD Cowen
TD Cowen raised the firm’s price target on Iqvia (IQV) to $213 from $174 and keeps a Buy rating on the shares. The firm does not see AI driving revenue…
Iqvia upgraded to Overweight from Equal Weight at Barclays
Barclays upgraded Iqvia (IQV) to Overweight from Equal Weight with an unchanged price target of $210. The firm sees upside to the stock’s valuation and and estimates. Iqvia’s history of…